Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Daiichi to market Nycomed imaging agent in Japan:

This article was originally published in Clinica

Executive Summary

Daiichi is to market Nycomed Amersham's ultrasound imaging agent, NC-100100, in Japan. The product will be used in cardiology and radiology applications, including liver imaging. It will be submitted for approval in the US and Europe at the end of this year. Development in Japan is at the preclinical stage. Daiichi already markets selected Nycomed imaging agents in Japan, including the non-ionic X-ray contrast medium, Omnipaque (iohexol). Nycomed Amersham estimates the potential worldwide market for ultrasound imaging to be around $1.6 billion.

You may also be interested in...



Abbott Capitalizes On Pandemic Testing Boom; Device Sales Stay Almost Flat

Abbott reported almost 28% revenue growth in the fourth quarter led by the exploding demand for COVID-19 tests and continued success of its FreeStyle Libre continuous glucose monitor.

Agios’ Mitapivat Shows Improvement In Regularly Transfused PKD Patients

While representing a smaller population, the ACTIVATE-T trial targeted patients seen as having greater unmet need.

Medtech Industry Favorite Wins Seat On Powerful House E&C Committee

As a freshman member on the US House Energy and Commerce Committee, former St. Jude Medical exec Rep. Angie Craig can help shape future health care, cybersecurity bills.

Topics

UsernamePublicRestriction

Register

OM013202

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel